The Journal and Authors retract the 28 October 2020 article cited above for the following reasons provided by the Authors:
Following publication, concerns were raised regarding data misrepresentation. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.
This retraction was approved by the Chief Editors of Frontiers in Oncology and Chief Executive Editor. The authors agreed to this retraction.
Summary
Keywords
Asparaginase, pegasapraginase, pancreatitits, childhood leukemia, Retrospective study
Citation
Frontiers Editorial Office (2021) Retraction: Peg-Asparaginase-Associated Pancreatitis in Chemotherapy-Treated Pediatric Patients: A 5-Year Retrospective Study. Front. Oncol. 11:709636. doi: 10.3389/fonc.2021.709636
Received
14 May 2021
Accepted
14 May 2021
Published
03 June 2021
Approved by
Rimas J. Orentas, Seattle Children’s Research Institute, United States
Volume
11 - 2021
Updates
Copyright
© 2021 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org
This article was submitted to Pediatric Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.